메뉴 건너뛰기




Volumn 25, Issue 5, 2011, Pages 675-684

Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis

Author keywords

antipsychotic agent; aripiprazole; dopamine agonist; health care cost; quality of life

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; FLUOXETINE; LITHIUM SALT; LORAZEPAM; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PIPOTIAZINE; PROCYCLIDINE; QUETIAPINE; REBOXETINE; RISPERIDONE; ZOPICLONE; ZUCLOPENTHIXOL;

EID: 79955400122     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109358198     Document Type: Article
Times cited : (5)

References (36)
  • 1
    • 0030796665 scopus 로고    scopus 로고
    • The cost-effectiveness of clozapine. A UK clinic-based study
    • Aitchison KJ, Kerwin RW. The cost-effectiveness of clozapine. A UK clinic-based study. Br J Psychiatry. 1997 ; 171: 125-130
    • (1997) Br J Psychiatry , vol.171 , pp. 125-130
    • Aitchison, K.J.1    Kerwin, R.W.2
  • 2
    • 33644821818 scopus 로고    scopus 로고
    • Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?
    • Annemans L. Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?. Pharmacoeconomics. 2005 ; 23 (suppl 1). 1-2
    • (2005) Pharmacoeconomics , vol.23 , Issue.SUPPL. 1 , pp. 1-2
    • Annemans, L.1
  • 3
    • 27644545591 scopus 로고    scopus 로고
    • Head-to-head comparison of the costs of atypical antipsychotics: A systematic review
    • DOI 10.2165/00023210-200519110-00004
    • Barbui C, Lintas C, Percudani M. Head-to-head comparison of the costs of atypical antipsychotics: a systematic review. CNS Drugs. 2005 ; 19: 935-950 (Pubitemid 41571993)
    • (2005) CNS Drugs , vol.19 , Issue.11 , pp. 935-950
    • Barbui, C.1    Lintas, C.2    Percudani, M.3
  • 7
    • 0033830383 scopus 로고    scopus 로고
    • Causes of the excess mortality of schizophrenia
    • Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000 ; 177: 212-217
    • (2000) Br J Psychiatry , vol.177 , pp. 212-217
    • Brown, S.1    Inskip, H.2    Barraclough, B.3
  • 8
    • 42149127173 scopus 로고    scopus 로고
    • Canterbury: Personal Social Services Research Unit, The University of Kent ;
    • Curtis L, Netten A Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, The University of Kent ; 2006 :
    • (2006) Unit Costs of Health and Social Care
    • Curtis, L.1    Netten, A.2
  • 9
    • 0027985147 scopus 로고
    • Economics and schizophrenia: The real cost
    • Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994 ; 25 (suppl). 18-21 (Pubitemid 24331669)
    • (1994) British Journal of Psychiatry , vol.165 , Issue.NOV. SUPPL. 25 , pp. 18-21
    • Davies, L.M.1    Drummond, M.F.2
  • 10
    • 34447131002 scopus 로고    scopus 로고
    • Cost-effectiveness of first- v. second-generation antipsychotic drugs: Results from a randomised controlled trial in schizophrenia responding poorly to previous therapy
    • DOI 10.1192/bjp.bp.106.028654
    • Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007 ; 191: 14-22 (Pubitemid 47035176)
    • (2007) British Journal of Psychiatry , vol.191 , Issue.JULY , pp. 14-22
    • Davies, L.M.1    Lewis, S.2    Jones, P.B.3    Barnes, T.R.E.4    Gaughran, F.5    Hayhurst, K.6    Markwick, A.7    Lloyd, H.8
  • 11
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • DOI 10.1001/archpsyc.60.6.553
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003 ; 60: 553-564 (Pubitemid 36682312)
    • (2003) Archives of General Psychiatry , vol.60 , Issue.6 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 12
    • 0030056579 scopus 로고    scopus 로고
    • Guidelines for authors and peer reviewers of economic submissions to the BMJ
    • Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996 ; 313: 275-283 (Pubitemid 26254740)
    • (1996) British Medical Journal , vol.313 , Issue.7052 , pp. 275-283
    • Drummond, M.F.1    Jefferson, T.O.2
  • 13
    • 0034145539 scopus 로고    scopus 로고
    • The new drugs (chlorpromazine and reserpine): Administrative aspects, 1956
    • Duval AM, Goldman D. The new drugs (chlorpromazine and reserpine): administrative aspects, 1956. Psychiatr Serv. 2000 ; 51: 327-331
    • (2000) Psychiatr Serv , vol.51 , pp. 327-331
    • Duval, A.M.1    Goldman, D.2
  • 15
    • 0033064214 scopus 로고    scopus 로고
    • Cost of schizophrenia to UK society: An incidence-based cost-of-illness model for the first 5 years following diagnosis
    • DOI 10.2165/00019053-199915060-00007
    • Guest JF, Cookson RF. Cost of schizophrenia to UK society: an incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics. 1999 ; 15: 597-610 (Pubitemid 29256520)
    • (1999) PharmacoEconomics , vol.15 , Issue.6 , pp. 597-610
    • Guest, J.F.1    Cookson, R.F.2
  • 16
    • 33644829405 scopus 로고    scopus 로고
    • Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectivness models
    • Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectivness models. Pharmacoeconomics. 2005 ; 23 (suppl 1). 3-16
    • (2005) Pharmacoeconomics , vol.23 , Issue.SUPPL. 1 , pp. 3-16
    • Haycox, A.1
  • 17
    • 0021154534 scopus 로고
    • The quality of life scale: An instrument for rating the schizophrenic deficit syndrome
    • Heinrichs DN, Hanton TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984 ; 10: 388-398
    • (1984) Schizophr Bull , vol.10 , pp. 388-398
    • Heinrichs, D.N.1    Hanton, T.E.2    Carpenter, W.T.3
  • 18
    • 33749321169 scopus 로고    scopus 로고
    • Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia
    • Jones PB, Barnes T.R.E, Davies L, et al. Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006 ; 63: 1079-1087
    • (2006) Arch Gen Psychiatry , vol.63 , pp. 1079-1087
    • Jones, P.B.1    Tre, B.2    Davies, L.3
  • 19
    • 33847623330 scopus 로고    scopus 로고
    • Predicting costs of mental health care: A critical literature review
    • DOI 10.1017/S0033291706009676, PII S0033291706009676
    • Jones J, Amaddeo F, Barbui C, Tansella M. Predicting costs of mental health care: a critical literature review. Psychol Med. 2007 ; 37: 467-477 (Pubitemid 46359596)
    • (2007) Psychological Medicine , vol.37 , Issue.4 , pp. 467-477
    • Jones, J.1    Amaddeo, F.2    Barbui, C.3    Tansella, M.4
  • 20
    • 34447117847 scopus 로고    scopus 로고
    • A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study
    • DOI 10.1016/j.eurpsy.2007.03.002, PII S0924933807012886
    • Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community treated schizophrenic patients Schzophrenia Trial of Aripiprazole: (STAR Study). Eur Psychiatry. 2007 ; 22: 433-443 (Pubitemid 47600616)
    • (2007) European Psychiatry , vol.22 , Issue.7 , pp. 433-443
    • Kerwin, R.1    Millet, B.2    Herman, E.3    Banki, C.M.4    Lublin, H.5    Pans, M.6    Hanssens, L.7    L'Italien, G.8    McQuade, R.D.9    Beuzen, J.-N.10
  • 21
    • 0030719980 scopus 로고    scopus 로고
    • Costs of schizophrenia
    • Knapp M. Costs of schizophrenia. Br J Psychiatry. 1997 ; 171: 509-518 (Pubitemid 27527318)
    • (1997) British Journal of Psychiatry , vol.171 , Issue.DEC. , pp. 509-518
    • Knapp, M.1
  • 22
    • 33745328794 scopus 로고    scopus 로고
    • Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
    • Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Rockv). 2006 ; 10: 1-165
    • (2006) Health Technol Assess (Rockv) , vol.10 , pp. 1-165
    • Lewis, S.W.1    Davies, L.2    Jones, P.B.3
  • 23
    • 25144456112 scopus 로고    scopus 로고
    • For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigator: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • Lieberman JA, Stroup TS, McEvoy JP, et al. For the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigator: effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223
    • (2005) N Engl J Med , vol.353 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 26
    • 33750069721 scopus 로고    scopus 로고
    • Raising the bar for treatment expectations in schizophrenia: Achieving remission as a routine goal of antipsychotic pharmacotherapy
    • DOI 10.1177/1359786806071221
    • Nasrallah HA, Dursun SM. Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy. J Psychopharmacol. 2006 ; 20 (suppl 6). 3-5 (Pubitemid 44583373)
    • (2006) Journal of Psychopharmacology , vol.20 , Issue.6 SUPPL. , pp. 3-5
    • Nasrallah, H.A.1    Dursun, S.M.2
  • 27
    • 33750073822 scopus 로고    scopus 로고
    • Improving patient outcomes in schizophrenia: Achieving remission
    • DOI 10.1177/1359786806071248
    • Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol. 2006 ; 20 (suppl 6). 57-61 (Pubitemid 44583377)
    • (2006) Journal of Psychopharmacology , vol.20 , Issue.6 SUPPL. , pp. 57-61
    • Nasrallah, H.A.1    Lasser, R.2
  • 28
    • 14744290059 scopus 로고    scopus 로고
    • Defining and measuring clinical effectiveness in the treatment of schizophrenia
    • DOI 10.1176/appi.ps.56.3.273
    • Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatr Serv. 2005 ; 56: 273-282 (Pubitemid 40333559)
    • (2005) Psychiatric Services , vol.56 , Issue.3 , pp. 273-282
    • Nasrallah, H.A.1    Targum, S.D.2    Tandon, R.3    McCombs, J.S.4    Ross, R.5
  • 30
    • 57749207241 scopus 로고    scopus 로고
    • Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia
    • Ohlsen RI, Taylor D, Tandon K, Aitchison KJ. Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of schizophrenia. Clin Neuropsychiatry, J Treatment Evaluation. 2008 ; 5 (4). 184-194
    • (2008) Clin Neuropsychiatry, J Treatment Evaluation , vol.5 , Issue.4 , pp. 184-194
    • Ohlsen, R.I.1    Taylor, D.2    Tandon, K.3    Aitchison, K.J.4
  • 32
    • 1642580680 scopus 로고    scopus 로고
    • Selection of Atypical Antipsychotics for the Management of Schizophrenia
    • DOI 10.1345/aph.1C461
    • Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother. 2004 ; 38: 313-319 (Pubitemid 38112247)
    • (2004) Annals of Pharmacotherapy , vol.38 , Issue.2 , pp. 313-319
    • Sprague, D.A.1    Loewen, P.S.2    Raymond, C.B.3
  • 33
    • 57749192240 scopus 로고    scopus 로고
    • The cost effectiveness of atypical versus typical antipsychotics
    • Tandon K, Aitchison KJ. The cost effectiveness of atypical versus typical antipsychotics. Psychiatry. 2002 ; 1: 66-69
    • (2002) Psychiatry , vol.1 , pp. 66-69
    • Tandon, K.1    Aitchison, K.J.2
  • 34
    • 0037214276 scopus 로고    scopus 로고
    • Efficacy of newer generation antipsychotics in the treatment of schizophrenia
    • DOI 10.1016/S0306-4530(02)00110-5
    • Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003 ; 28 (suppl 1). 9-26 (Pubitemid 36015659)
    • (2003) Psychoneuroendocrinology , vol.28 , Issue.SUPPL. 1 , pp. 9-26
    • Tandon, R.1    Jibson, M.D.2
  • 35
    • 33747481325 scopus 로고    scopus 로고
    • A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)
    • DOI 10.1016/j.schres.2005.12.857, PII S0920996406000144
    • Tandon R, Marcus RN, Stock EG, et al. A prospective, multicentre, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: broad effectiveness trial with aripiprazole (BETA). Schizophr Res. 2006 ; 84: 77-89 (Pubitemid 44255718)
    • (2006) Schizophrenia Research , vol.84 , Issue.1 , pp. 77-89
    • Tandon, R.1    Marcus, R.N.2    Stock, E.G.3    Riera, L.C.4    Kostic, D.5    Pans, M.6    McQuade, R.D.7    Nyilas, M.8    Iwamoto, T.9    Crandall, D.T.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.